Mesoblast Limited (MEOBF) Stock Price & Analysis
Mesoblast Limited (MEOBF) — price $1.14 (0.00%), as of the Nov 19, 2026 trading session; market cap $1.48B.
Educational signal · not a buy or sell recommendation · How to read this
Mesoblast Limited · MEOBF
Mesoblast Limited is a biopharmaceutical company focused on developing and commercializing allogeneic cellular medicines across multiple therapeutic areas. The company leverages its proprietary mesenchymal lineage cell technology platform with several product candidates in Phase III clinical trials for conditions such as heart failure and graft versus host disease.
Price as of Nov 19, 2026
Key Statistics
Not scored: MoonshotScore covers actively traded US operating companies, not funds, preferred shares, warrants or thinly traded stocks.
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $1.14 | |
| Change on the day | 0.00% | |
| 52-week range | $1.14 – $2.05 | |
| Market capitalisation | $1.48B | |
| Shares traded on the day | 100 |
Price & events
Other perspectives
Council score for Mesoblast (MEOBF): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 9, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 9, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Mesoblast (MEOBF), and what does it report?
Short answer · as of
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Mesoblast Limited (MEOBF) is the company analyzed here. It employs 108 people and is led by Silviu Itescu. In Q4 FY2026 it reported revenue of $37M and net income of -$9M. The market values it at $1.48B.
What do the latest results show for Mesoblast (MEOBF)?
Short answer · as of
The most recent reported quarter, Q4 FY2026, carried revenue of $37M. Against analyst estimates the company has EPS beat 4 of the last 8 reports.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 FY2026 | $37M | -$9M | -$0.01 (diluted) |
| Q3 FY2026 | $34M | -$9M | -$0.01 (diluted) |
| Q2 FY2026 | $26M | -$20M | -$0.02 (diluted) |
| Q1 FY2026 | $26M | -$20M | -$0.02 (diluted) |
What are the financial strengths and risks for Mesoblast (MEOBF)?
Short answer · as of
The distress and quality screens read Altman Z 2.53 · Piotroski F 3. Trailing ratios: ROE -9.9% · ROA -4.1% · current ratio 2.44.
Data-derived red flags
- Negative return on equity (-9.9%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
The records behind this page
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held MEOBF in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported MEOBF in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
Mesoblast Stock: Key Questions Answered
These answers are editorial: 1 of these 8 answers is drawn from the MEOBF research dossier (written Jun 14, 2026 by gemini-2.5-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.
Is MEOBF a good stock to buy?
Stock Expert AI does not rate MEOBF buy, sell or hold. Mesoblast Limited has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the MEOBF stock price today?
The last price recorded for Mesoblast Limited (MEOBF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
How does Mesoblast Limited differentiate its allogeneic cellular medicines from other therapies?
Mesoblast Limited differentiates its allogeneic cellular medicines through its proprietary mesenchymal lineage cell technology platform. Unlike autologous therapies, which use a patient's own cells and require individualized processing, Mesoblast's allogeneic approach utilizes donor cells, allowing for off-the-shelf availability.
What are the key factors to evaluate for MEOBF?
Evaluate MEOBF on fundamentals, analyst consensus, and risk factors. Not financial advice.
How frequently does MEOBF data refresh on this page?
MEOBF's price is the last quote we recorded, from the Nov 19, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven MEOBF's recent stock price performance?
Mesoblast Limited (MEOBF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary mesenchymal lineage cell technology platform with broad therapeutic potential. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MEOBF overvalued or undervalued right now?
Mesoblast Limited (MEOBF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MEOBF before investing?
Before investing in Mesoblast Limited (MEOBF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Machine-generated analysis by Stock Expert AI — model gemini-2.5-flash, generated Jun 14, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 9 from Financial Modeling Prep (FMP) and 5 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com